Translational Research of Liver Cancer

Dear Colleagues,

The incidence of livers cancers has more than tripled over the past 30 years.

Significant progress has been made recently with regard to treatment options, and in addition to immunotherapies and anti-angiogenic agents, targeted therapies have been approved for specific molecular subsets.

The growing number of treatment options for primary livers cancers, i.e., mainly hepatocellular carcinomas and intrahepatic cholangiocarcinomas, requires novel advances in biomarker discovery, patient stratification, and treatment sequencing more than ever.

In this Special Edition, I would like to highlight cutting-edge translational work which might hopefully shed more light into the biology of primary liver cancers and also guide the necessary next steps in developing better treatment strategies for patients at all stages of liver cancer.

Your translational research has significantly contributed to the field beyond pure drug development, and I would like to invite you to share your work with other colleagues around the globe.

I look forward to your response.

Prof. Dr. Farshid Dayyani

Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.